1-4 of 4
Philip J. Byrd
Close
Sort by
Journal Articles

PALB2 Mutational Status in Haematopoeitic Malignancies - a Potential Therapeutic Target?

Ceri Oldreive, PhD BSc, Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Anna Smith, Alexander J Taylor, Peggy Fooks, Robert Horsley, James I Last, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, A. Malcolm R Taylor
Journal: Blood
Blood (2016) 128 (22): 2726.
https://doi.org/10.1182/blood.V128.22.2726.2726
Published: 2016
Journal Articles

A Novel Role of PALB2 in Lymphoid Tumour Development

Tatjana Stankovic, MD PhD, Philip J Byrd, PhD, Grant S Stewart, PhD, Alexander J Taylor, Anna Smith, Peggy Fooks, Robert Horsley, James I Last, PhD, Dragana Janic, MD PhD, Lidija Dokmanovic, MD PhD, Antony W Oliver, PhD, A.Malcolm R Taylor, PhD
Journal: Blood
Blood (2016) 128 (22): 5113.
https://doi.org/10.1182/blood.V128.22.5113.5113
Published: 2016
Journal Articles

Microarray analysis reveals that TP53 - and ATM -mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

Tatjana Stankovic, Mike Hubank, Debbie Cronin, Grant S. Stewart, Danielle Fletcher, Colin R. Bignell, Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, Philip J. Byrd, Paul A. H. Moss, A. Malcolm R. Taylor
Journal: Blood
Blood (2004) 103 (1): 291–300.
https://doi.org/10.1182/blood-2003-04-1161
Published: 2004
Journal Articles

Ataxia telangiectasia mutated–deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage

Tatjana Stankovic, Grant S. Stewart, Christopher Fegan, Paul Biggs, James Last, Philip J. Byrd, Russell D. Keenan, Paul A. H. Moss, Alexander M. R. Taylor
Journal: Blood
Blood (2002) 99 (1): 300–309.
https://doi.org/10.1182/blood.V99.1.300
Published: 2002